Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...
Genetic testing showed that childhood cancer survivors aged faster biologically, regardless of the treatment they received as ...
From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...
A new study headed by teams at the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), and Open Targets has indicated how mutations that cause cancer drug resistance fall ...
In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...
How bladder cancer originates and progresses has been illuminated as never before. Researchers found that antiviral enzymes that mutate the DNA of normal and cancer cells are key promoters of early ...
The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...
On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...
From hair regrowth to safe pregnancy chemotherapy and new targeted therapies, these top five breast cancer stories of 2025 ...
A lung cancer diagnosis can feel frightening. And when a family member is diagnosed, you might wonder about your own risk, prompting you to ask if lung cancer is hereditary. Smoking tobacco accounts ...
As individuals, we can’t do much about microplastics. A lot of it ends up in the oceans, the fish are ingesting it and we’re ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback